Please login to the form below

Not currently logged in
Email:
Password:

Verona names David Ebsworth as non-executive chairman

He joins from Vifor Pharma
Verona names David Ebsworth as non-executive chairman

Verona Pharma has appointed Dr David Ebsworth as its non-executive chairman of the board of directors.

Ebsworth's role will be effective from December 1 when he will take over from Prof Clive Page, who has held the position since founding the company in 2006.

Ebsworth (pictured) is an experienced pharma executive who has worked at board and senior management level at a number of international companies. He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser for both firms.

His career in the pharma industry spans over 35 years, including a 19-year stint at Bayer where he worked up through the company from product manager to general manager of the global pharma division.

Commenting on his appointment, Ebsworth said: “I am looking forward to working closely with Verona Pharma's board and management to guide the company towards success. I shall use my background and experience in both international pharma and biotech to support this innovative company within the hugely rewarding respiratory space.”

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We thank Clive for all his achievements as we welcome David to the board. David' significant expertise in the pharma industry strongly supports Verona Pharma's focus on high value commercial opportunities and future growth.”

24th November 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics